CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- FinancialsAltman Z-Score 8.3: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
3.27%
Annual Rate
CNY 1.00Paid semi-annual
Payout Ratio
79.9%Moderate
Payback Period
38.0 yr
Last Ex-Dividend
May 26, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.06BCNY454.76M · vs all stocks (USD)
Trailing P/E
35.50xvs Medical Devices peers
Revenue (TTM)
412.52MCNY61.35M · vs all stocks (USD)
Profit Margin
20.77%vs Medical Devices peers
Beta
0.4700xvs all stocks
52-Week Change
-31.95%vs all stocks
Forward Annual Dividend Yield
3.27%vs all stocks
Market Capitalization
3.06BCNY454.76M · vs all stocks (USD)
Enterprise Value
2.33BCNY345.87M · vs all stocks (USD)
Trailing P/E
35.50xvs Medical Devices peers
Price to Sales (TTM)
7.57xvs Medical Devices peers
Price to Book (MRQ)
2.23xvs Medical Devices peers
Enterprise to Revenue
5.64xvs Medical Devices peers
Enterprise to EBITDA
26.74xvs Medical Devices peers
Gross Margin
66.92%vs Medical Devices peers
Profit Margin
20.77%vs Medical Devices peers
Operating Margin
23.96%vs Medical Devices peers
Return on Assets (TTM)
2.60%vs Medical Devices peers
Return on Equity (TTM)
5.98%vs Medical Devices peers
Revenue (TTM)
412.52MCNY61.35M · vs all stocks (USD)
Revenue per Share (TTM)
4.22CNYUpdated Aug 21, 2026Quarterly Revenue Growth
-16.10%vs Medical Devices peers
Gross Profit (TTM)
283.23MCNY42.12M · vs all stocks (USD)
EBITDA (TTM)
103.46MCNY15.39M · vs all stocks (USD)
Net Income (TTM)
85.70MCNY12.74M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-42.50%vs Medical Devices peers
Operating Cash Flow (TTM)
92.95MCNY13.82M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
30.18MCNY4.49M · vs all stocks (USD)
Forward Annual Dividend Rate
1.00CNYUpdated Aug 21, 2026Forward Annual Dividend Yield
3.27%vs all stocks
Trailing Annual Dividend Rate
0.8000CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
2.62%vs all stocks
Payout Ratio
79.88%vs Medical Devices peers
Minority Interest (Equity)
24.44MCNYFY2025 · Dec 31, 2025Revenue
431.59MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
128.60MCNYFY2025 · Dec 31, 2025Gross Profit
303.00MCNYFY2025 · Dec 31, 2025Operating Income
101.77MCNY15.13M · vs all stocks (USD)
Pre-tax Income
106.35MCNYFY2025 · Dec 31, 2025Income Tax Expense
6.52MCNYFY2025 · Dec 31, 2025Net Income
99.83MCNYFY2025 · Dec 31, 2025EBIT
107.74MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
141.94MCNYFY2025 · Dec 31, 2025Research & Development
61.27MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
61.63MCNYFY2025 · Dec 31, 2025Other Operating Expenses
4.34MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
2.07MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
1.39MCNYFY2025 · Dec 31, 2025EPS (Basic)
1.05CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.05CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
97.82MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
97.82MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
99.83MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
2.80MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
79.58MCNYFY2025 · Dec 31, 2025Free Cash Flow
-38.22MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
814.50MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
99.83MCNYFY2025 · Dec 31, 2025Other Non-cash Items
3.81MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-12.54MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-11.51MCNYFY2025 · Dec 31, 2025Capital Expenditures
-117.80MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.86BCNYFY2025 · Dec 31, 2025Sale of Investments
2.32BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
343.37MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
19.02MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-13.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-68.70MCNYFY2025 · Dec 31, 2025Other Financing Charges
-12.68MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-75.36MCNYFY2025 · Dec 31, 2025Shares Outstanding
100.00MSharesUpdated Aug 21, 2026Float Shares
31.57MSharesUpdated Aug 21, 2026% Held by Insiders
66.13%vs all stocks
% Held by Institutions
2.93%vs all stocks
Total Cash (MRQ)
788.00MCNY117.18M · vs all stocks (USD)
Total Cash per Share (MRQ)
8.06CNYUpdated Aug 21, 2026Total Debt (MRQ)
35.60MCNY5.29M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0256xvs Medical Devices peers
Current Ratio (MRQ)
4.89xvs Medical Devices peers
Book Value per Share (MRQ)
14.01CNYUpdated Aug 21, 2026Total Assets
1.63BCNY242.29M · vs all stocks (USD)
Total Current Assets
930.81MCNYFY2025 · Dec 31, 2025Total Liabilities
259.67MCNYFY2025 · Dec 31, 2025Total Non-current Assets
698.46MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
38.89MCNYFY2025 · Dec 31, 2025Total Current Liabilities
220.78MCNYFY2025 · Dec 31, 2025Cash
815.87MCNYFY2025 · Dec 31, 2025Cash Equivalents
582.79KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
816.45MCNYFY2025 · Dec 31, 2025Accounts Receivable
27.54MCNYFY2025 · Dec 31, 2025Inventory
71.99MCNYFY2025 · Dec 31, 2025Accounts Payable
94.81MCNYFY2025 · Dec 31, 2025Short-term Debt
24.08MCNYFY2025 · Dec 31, 2025Other Current Liabilities
3.55MCNYFY2025 · Dec 31, 2025Long-term Debt
9.49MCNYFY2025 · Dec 31, 2025Common Stock (Book)
100.00MCNYFY2025 · Dec 31, 2025Retained Earnings
262.98MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.37BCNY203.67M · vs all stocks (USD)
Treasury Stock
53.58MCNYFY2025 · Dec 31, 202552-Week Low
27.18CNYUpdated Aug 21, 202652-Week High
61.22CNYUpdated Aug 21, 202652-Week Change
-31.95%vs all stocks
Beta
0.4700xvs all stocks
50-Day MA
35.02CNYUpdated Aug 21, 2026200-Day MA
40.92CNYUpdated Aug 21, 2026Avg 10-Day Volume
1.10MSharesUpdated Aug 21, 2026Avg 30-Day Volume
1.48MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
0.8800CNYUpdated Aug 21, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
How does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 8.3: safe zoneNotable
Altman Z-Score: 8.30
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
ClearPoint Neuro Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Zhejiang Shouxiangu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ever Supreme Bio Technology Co., Ltd
Tier 1ProductionApproval-Gated PipelineRuleFlow
Prothena Corporation plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Allergy Therapeutics plc
Tier 1ProductionApproval-Gated PipelineRule
Kyverna Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guizhou Yibai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Editas Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guanhao Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shaanxi Panlong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Johnson Fine Chemical Co., Ltd.
2 interpretationsIndustry-Benchmarked ROA and Margin ElevatedCash Elevated Relative to Current Liabilities and Total Assets
Liaoning Chengda Biotechnology Co., Ltd.
2 interpretationsIndustry-Benchmarked ROA and Margin ElevatedCash Elevated Relative to Current Liabilities and Total Assets
King Slide Works Co., Ltd.
2 interpretationsIndustry-Benchmarked ROA and Margin ElevatedCash Elevated Relative to Current Liabilities and Total Assets